- Home
- MPB vs KROS Comparison
MPB vs KROS Comparison
Compare MPB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- KROS
- Stock Information
- Founded
- MPB 1868
- KROS 2015
- Country
- MPB United States
- KROS United States
- Employees
- MPB N/A
- KROS N/A
- Industry
- MPB Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- KROS Health Care
- Exchange
- MPB Nasdaq
- KROS Nasdaq
- Market Cap
- MPB 691.1M
- KROS 565.0M
- IPO Year
- MPB N/A
- KROS 2020
- Fundamental
- Price
- MPB $30.71
- KROS $15.62
- Analyst Decision
- MPB Buy
- KROS Buy
- Analyst Count
- MPB 2
- KROS 14
- Target Price
- MPB $34.50
- KROS $20.56
- AVG Volume (30 Days)
- MPB 82.5K
- KROS 412.4K
- Earning Date
- MPB 10-22-2025
- KROS 11-05-2025
- Dividend Yield
- MPB 2.60%
- KROS N/A
- EPS Growth
- MPB N/A
- KROS N/A
- EPS
- MPB 2.30
- KROS 0.47
- Revenue
- MPB $191,454,000.00
- KROS $232,844,000.00
- Revenue This Year
- MPB $24.57
- KROS $5,998.31
- Revenue Next Year
- MPB $12.23
- KROS N/A
- P/E Ratio
- MPB $13.35
- KROS $33.74
- Revenue Growth
- MPB 13.34
- KROS 85820.30
- 52 Week Low
- MPB $22.50
- KROS $9.12
- 52 Week High
- MPB $33.87
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MPB 66.81
- KROS 57.13
- Support Level
- MPB $29.94
- KROS $15.34
- Resistance Level
- MPB $30.44
- KROS $15.85
- Average True Range (ATR)
- MPB 0.60
- KROS 0.45
- MACD
- MPB -0.02
- KROS -0.02
- Stochastic Oscillator
- MPB 79.70
- KROS 57.08
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.